Chicago-based AbbVie Inc. has begun a second Phase 3 trial of San Diego-based Neurocrine Bioscience Inc.’s drug Elagolix that treats uterine fibroids and endometriosis.
Neurocrine Biosciences said that it is on track for a 2016 New Drug Application filing with the Food and Drug Administration.
The two companies entered a collaboration and license agreement for the hormone-based drug in 2010.
Stock for Neurocrine Biosciences, a $1 billion market cap company, closed at $14.98 on August 29.
— Meghana Keshavan